Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 102, Issue 8, 2014, Pages 1817-1824

  Gore, Savannah ^a   Andersson, Jonas ^b   Biran, Roy ^a   Underwood, Clayton ^a   Riesenfeld, Johan ^b  

^a W L GORE AND ASSOCIATES   (United States)

^b Carmeda AB   (Sweden)

Author keywords

Antithrombin; Hemocompatibility; Heparin; Immobilized; Thromboresistance

Indexed keywords

AMINES; CHEMICAL ACTIVATION; CHEMICAL BONDS; CHLORINE COMPOUNDS; PLATELETS; POLYVINYL CHLORIDES; PROTEINS;

ANTITHROMBIN; HEMOCOMPATIBILITY; HEPARIN; IMMOBILIZED; THROMBORESISTANCE;

POLYSACCHARIDES;

ANTITHROMBIN; BETA THROMBOGLOBULIN; END POINT ATTACHED HEPARIN; HEPARIN; MEMBRANE PROTEIN; NITROUS ACID; PLASMA PROTEIN; POLYVINYLCHLORIDE; UNCLASSIFIED DRUG; BIOMATERIAL;

ADSORPTION; AMINATION; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; HEMOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMOBILIZATION; IN VITRO STUDY; MATERIAL COATING; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN INTERACTION; SURFACE PROPERTY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; CHEMISTRY; MATERIALS TESTING; METABOLISM; THROMBOCYTE; THROMBOCYTE ADHESION;

ADSORPTION; BLOOD PLATELETS; BLOOD PROTEINS; COATED MATERIALS, BIOCOMPATIBLE; HEPARIN; HUMANS; MATERIALS TESTING; PLATELET ADHESIVENESS; SURFACE PROPERTIES;

EID: 84908117922     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.33154     Document Type: Article

References (28)

1. Wendel HP, Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg 1999;16:342-350.
2. Tanzi MC. Bioactive technologies for hemocompatibility. Expert Rev Med Devices 2005;2:473-492.
3. Larsson R. Heparin binding to improve biocompatibility. In: Wnek GE, Bowlin GL, editors. Encyclopedia of Biomaterials and Biomedical Engineering. New York: Informa; 2008. p 1368.
4. Belway D, Rubens FD. Currently available biomaterials for use in cardiopulmonary bypass. Expert Rev Med Devices 2006;3:345-355.
5. Murugesan S, Xie J, Linhardt RJ. Immobilization of heparin: Approaches and applications. Curr Top Med Chem 2008;8:80-100.
6. Kodama K, Pasche B, Olsson P, Swedenborg J, Adolfsson L, Larm O, Riesenfeld J. Antithrombin III binding to surface immobilized heparin and its relation to F Xa inhibition. Thromb Haemost 1987; 58:1064-1067.
7. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 1998;89:41-50.
8. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Control of contact activation on end-point immobilized heparin: The role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res 1995;29:655-661.
9. Sefton MV, Gemmell CH, Gorbet MB. Nonthrombogenic treatments and strategies. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE, editors. Biomaterials Science, 3rd ed. An Introduction to Materials in Medicine. New York: Elsevier; 2012. pp 1488-1509.
10. Weber N, Wendel HP, Ziemer G. Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes. J Biomater Appl 2000;15:8-22.
11. Cornelius RM, Sanchez J, Olsson P, Brash JL. Interactions of antithrombin and proteins in the plasma contact activation system with immobilized functional heparin. J Biomed Mater Res A 2003;67:475-483.
12. Larm O, Lins LE, Olsson P. An approach to anti-thrombosis by surface modification. In: Kjellstrand C, Nose Y, editors. Progress in Artificial Organs. Cleveland: ISAIO Press; 1986. pp 313-318.
13. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983;11(2-3):161-173.
14. Lin PH, Chen C, Bush RL, Yao Q, Lumsden AB, Hanson SR. Smallcaliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg 2004; 39:1322-1328.
15. Lin PH, Bush RL, Yao Q, Lumsden AB, Chen C. Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model. J Surg Res 2004;118:45-52.
16. Kocsis JF, Llanos G, Holmer E. Heparin-coated stents. J Long Term Eff Med Implants 2000;10(1-2):19-45.
17. Mollnes TE, Videm V, Christiansen D, Bergseth G, Riesenfeld J, Hovig T. Platelet compatibility of an artificial surface modified with functionally active heparin. Thromb Haemost 1999;82:1132-1136.
18. Lappegard KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, Mollnes TE. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 2008;87:129-135.
19. Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, Mollnes TE. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg 2004;77:932-941.
20. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gallhagen A. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg 2003;25:432-437.
21. Lindholt JS, Gottschalksen B, Johannesen N, Dueholm D, Ravn H, Christensen ED, Viddal B, Florenes T, Pedersen G, Rasmussen M, et al. The Scandinavian Propaten((R)) trial-1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses-A randomised clinical controlled multi-centre trial. Eur J Vasc Endovasc Surg 2011;41:668-673.
22. Arnander C, Olsson P, Larm O. Influence of blood flow and the effect of protamine on the thromboresistant properties of a covalently bonded heparin surface. J Biomed Mater Res 1988;22:859-868.
23. Hook M, Bjork I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976;66:90-93.
24. Keuren JF, Wielders SJ, Driessen A, Verhoeven M, Hendriks M, Lindhout T. Covalently-bound heparin makes collagen thromboresistant. Arterioscler Thromb Vasc Biol 2004;24:613-617.
25. Hennink WE, Feijen J, Ebert CD, Kim SW. Covalently bound conjugates of albumin and heparin: synthesis, fractionation and characterization. Thromb Res 1983;29:1-13.
26. Smith RL, Gilkerson E. Quantitation of glycosaminoglycan hexosamine using 3-methyl-2-benzothiazolone hydrazone hydrochloride. Anal Biochem 1979;98:478-480.
27. Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A 2003;67:458-466.
28. Paul A, Straub A, Weber N, Ziemer G, Wendel HP. CD41 Western blotting: A new method to detect platelet adhesion to artificial surfaces used in extracorporeal circulation procedures. J Mater Sci Mater Med 2009;20:373-378.